Discovery, analysis, and quality control of Ag-specific T cells targeting solid cancers [WEBINAR]

For more information on robust flow cytometry-based analytical solutions, visit www.miltenyibi... In a compelling illustration of successful methods for TCR-based therapy development, Miltenyi Biotec R&D scientists Marc Schuster and Marek Wieczorek deliver expert advice on TCR identification and quality control assay design. With decades of experience in T cell analysis, they discuss the latest approaches to identify tumor-specific TCRs and develop the corresponding robust assays for in-process controls (IPC), release testing (RT), and patient immune monitoring. They also introduce the use of MHC multimers in flow cytometry assays to enhance quality assessment processes and support advancing therapeutic products through the development pipeline.
Streamlined and robust analytics for cell and gene therapy (CGT) is a pivotal aspect of advancing today’s therapeutic innovations. Miltenyi Biotec provides reagents, instruments, and services for a complete flow cytometry-based analytics workflow. These integrated solutions are designed to deliver reliable results and accommodate the specific needs of different drug development stages.
Miltenyi Biotec is a global leader innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to sets industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 4,900 employees across 24 countries.